Evidence map›Paper›PMID 38994012›Full record

ArticleFrontiers in endocrinology2024

Kidney outcomes with SGLT2is for type 2 diabetes patients: does background treatment with metformin or RASis matter?

Kah Suan Chong, Yi-Hsin Chang, Meng-Hsuan Lin, Chien-Ning Hsu, Chi-Chuan Wang, Chih-Yuan Wang, Yun-Lin Huang, Fang-Ju Lin, Huang-Tz Ou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kah Suan Chong *Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yi-Hsin Chang *Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Meng-Hsuan LinSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chien-Ning HsuDepartment of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Chi-Chuan WangSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chih-Yuan WangCollege of Medicine, National Taiwan University, Taipei, Taiwan.
Yun-Lin HuangSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Fang-Ju LinSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Huang-Tz OuInstitute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There is a lack of real-world evidence regarding the impact of concomitant metformin and renin-angiotensin system inhibitors (RASis) on sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated kidney outcomes. This study was aimed to investigate whether SGLT2i-associated kidney outcomes were modified by the concomitant use of metformin or RASis in patients with type 2 diabetes. Methods: SGLT2i users were identified from three electronic health record databases during May 2016 and December 2017 and categorized into those with and without concomitant use of metformin or RASis. Propensity score matching was performed to minimize baseline differences between groups. Study outcomes were mean estimated glomerular filtration rate (eGFR) change and time to 30%, 40%, and 50% eGFR reductions. A meta-analysis was performed to combine the estimates across databases. Results: After matching, there were 6,625 and 3,260 SGLT2i users with and without metformin, and 6,654 and 2,746 SGLT2i users with and without RASis, respectively. The eGFR dip was similar in SGLT2i users with and without metformin therapy, but was greater in SGLT2i users with RASis compared to those without RASis. Neither metformin nor RASi use had a significant effect on SGLT2i-associated eGFR reductions, as evidenced by the hazard ratios (95% CIs) of 30% eGFR reductions for SGLT2is with versus without metformin/RASis, namely 1.02 (0.87-1.20)/1.09 (0.92-1.31). Such findings were also observed in the outcomes of 40% and 50% eGFR reductions. Conclusion: Using metformin or RASis did not modify SGLT2i-associated kidney outcomes in type 2 diabetes.

Indexed as

Diabetes Mellitus, Type 2Glomerular Filtration RateHypoglycemic AgentsMetforminSodium-Glucose Transporter 2 InhibitorsAgedAngiotensin-Converting Enzyme InhibitorsFemaleHumansKidneyMaleMiddle AgedRenin-Angiotensin SystemRetrospective StudiesTreatment OutcomeAngiotensin-Converting Enzyme InhibitorsHypoglycemic AgentsMetforminSodium-Glucose Transporter 2 Inhibitorsestimated glomerular filtration ratekidney functionmetforminrenin-angiotensin system inhibitorssodium-glucose cotransporter-2 inhibitors

Identifiers

PMID38994012
PMCPMC11236716

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.